Semax: 10MG

£27.99

Purity: ≥ 99%

£27.99

Semax: 10MG

Name: Semax: 10MG
Brand: Pure Grade Labs
Price: 27.99 GBP
Availability: OutOfStock

£27.99

Purity: ≥ 99%

£27.99

NEUROPROTECTION - Brain protection & neurological recovery research

BDNF UPREGULATION - Brain cell growth & neuroplasticity research

COGNITIVE / NOOTROPIC - Memory, learning & cognitive function research

NEUROTRANSMITTER - Serotonin, dopamine & mood pathway research

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It is derived from the ACTH(4-7) fragment of adrenocorticotropic hormone - a four-amino-acid sequence at the N-terminal domain of ACTH - extended at the C-terminus with the tripeptide Pro-Gly-Pro to substantially increase metabolic stability and extend its duration of bioactivity compared to the unmodified ACTH fragment. Semax was first described in scientific literature in 1991 and was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has been registered as a pharmaceutical in Russia and Ukraine since 1994 for the clinical treatment of ischemic stroke, dyscirculatory encephalopathy, optic nerve atrophy, and cognitive disorders.

A critical structural distinction separates Semax from full-length ACTH: despite retaining the neurotrophic properties of the ACTH(4-10) fragment, Semax lacks the hormonal activity of the complete ACTH molecule and does not stimulate cortisol production from the adrenal glands. This makes it pharmacologically unique as an ACTH-derived compound without HPA axis involvement. Its primary studied mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, alongside modulation of serotonergic, dopaminergic, and cholinergic neurotransmitter systems. Semax has also been shown to inhibit enzymes responsible for enkephalin degradation, a mechanism shared with Selank.

Origin & Design: Derived from the ACTH(4-7) neurotrophic fragment of adrenocorticotropic hormone. The C-terminal Pro-Gly-Pro tripeptide was added to extend metabolic stability from minutes to approximately 20-24 hours, making it viable as a research and clinical compound. Does not produce cortisol release or other hormonal effects of full ACTH.

Research Context: Approved as a prescription drug in Russia and Ukraine for stroke and cognitive disorders. Human clinical data exists from Russian controlled trials, primarily in stroke recovery populations. The majority of published research originates from Russian institutions and has limited independent Western replication. Widely studied for BDNF upregulation, neuroprotection, and cognitive function in animal models.

Amino Acid Sequence: H-Met-Glu-His-Phe-Pro-Gly-Pro-OH

Molecular Formula: C37H51N9O10S

Molecular Weight: 813.9 g/mol

CAS Number: 80714-61-0

Form: Lyophilised Solid

The following summaries are drawn from peer-reviewed publications. Semax has a more extensive human clinical evidence base than most research peptides, though the majority of trials were conducted in Russia and have limited Western-language publication. Pure Grade Labs does not interpret these findings as evidence of efficacy for any specific indication.

Zhurnal Nevrologii i Psikhiatrii: Effectiveness of Semax in the acute period of hemispheric ischemic stroke: a clinical and electrophysiological study

Journal of Molecular Neuroscience: Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia

Zhurnal Nevrologii i Psikhiatrii: The efficacy of Semax in the treatment of patients at different stages of ischemic stroke

References

https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/

https://pmc.ncbi.nlm.nih.gov/articles/PMC8855339/

https://pmc.ncbi.nlm.nih.gov/articles/PMC8226508/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12755871/

https://pubmed.ncbi.nlm.nih.gov/24661604/

https://pubmed.ncbi.nlm.nih.gov/41479572/

https://pubmed.ncbi.nlm.nih.gov/20617398/

https://pubmed.ncbi.nlm.nih.gov/16996699/

https://pubmed.ncbi.nlm.nih.gov/16635254/

https://pubmed.ncbi.nlm.nih.gov/26552305/

Every batch of Semax supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Semax is supplied as a lyophilised (freeze-dried) solid. As a heptapeptide containing methionine, Semax is susceptible to oxidative degradation and requires careful handling to prevent methionine sulphoxidation, which can reduce biological activity. Follow the specifications below for optimal compound integrity.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to avoid condensation on the lyophilised cake.
Use bacteriostatic water (BAC water) or sterile saline as the reconstitution solvent. Semax is water-soluble and dissolves readily in aqueous solution. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl until fully dissolved. Do not vortex or shake vigorously. Semax dissolves easily and does not require heat or prolonged agitation.
Once reconstituted, store at 2-8°C and protect from light. Use within 14 days. Degradation of reconstituted Semax is accelerated compared to the lyophilised form. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

Semax supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. This product is not approved for human or veterinary use by any regulatory authority, including the FDA, MHRA, TGA, or EMA.

This product is not a drug, medicine, or supplement and must not be used as such.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans.
This product must not be administered to humans or animals outside of a licensed research context.
Semax is registered as a pharmaceutical drug in Russia and Ukraine for stroke and cognitive disorder indications. It does not hold approval from the FDA, EMA, MHRA, TGA, or equivalent regulatory authorities in other jurisdictions. In the United States, it may be available only through licensed 503A compounding pharmacies by prescription.
Although Semax does not activate the HPA axis or stimulate cortisol production, its ACTH-derived structure may carry implications for studies involving related receptor pathways. Researchers should review all relevant pharmacology before study design.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.